Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q9UIJ5 (Rec)
 58,342 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Due to the impact of the dairy quota system, the commercial use of goats for the production of milk and associated products is attractive to farmers diversifying their dairy interest. Intensification of milking and the expansion of herds will inevitably increase the incidence of caprine mastitis. The pharmaceutical industry and the veterinary surgeon will be required to provide data and advice upon the performance of currently available bovine intramammary products when used in the goat. This study produced evidence that one available bovine intramammary product, when infused into the glands of milking goats, produced a withholding time approximately double that defined for the cow. Following a course of infusions after three successive milkings, milk was not available for human consumption or for the production of cheese and yoghurt until 112 hours after the final infusion. This situation is likely to be representative of that which will occur for other currently available bovine intramammaries when prescribed in the goat.
Vet Rec 1989 Sep 09
PMID:Antibiotic persistence and tolerance in the lactating goat following intramammary therapy. 281 94

In most cases, maedi-visna virus infection is characterised by a subclinical, persistent virus-carrier state. However, in heavily infected flocks, economically significant disease does occur, mainly apparent as ill-thrift and chronic respiratory disease (maedi) in older ewes and as an indurative mastitis, which can result in delayed weight gain of suckled lambs. Meningoencephalitis (visna) and arthritis may also occur. Maedi-visna virus, a lentivirus, replicates via proviral intermediary DNA copies of its RNA genome in circulating monocytes, in which replication is highly restricted, and in tissue macrophages, where viral genome expression is more evident. The presence of macrophages expressing viral antigens on their surface in lungs, udder, joints or central nervous system tissues provides a focus for a local mononuclear cell inflammatory response. Factors which may contribute to macrophage activation and the development of the inflammatory response are discussed in the context of virus replication, transmission of infection and disease susceptibility.
Vet Rec 1987 May 09
PMID:Pathogenesis of maedi-visna. 303 58

Eight hundred and forty-eight strains of Staphylococcus aureus and coliforms isolated from milk samples taken from cows with clinical or subclinical mastitis were tested for their sensitivity to a range of antibiotics, comparing strains isolated in 1984, 1985, 1986 and 1987. The only increase in the proportion of resistant strains occurred with coliforms resistant to ampicillin and neomycin.
Vet Rec 1988 Nov 12
PMID:Antibiotic sensitivity of bovine staphylococcal and coliform mastitis isolates over four years. 320 94

Subclinical mastitis caused by streptococcal infections affected 27 of 83 cows in a commercial dairy herd. Between three and six weeks after intramammary treatment of these cows with cloxacillin, 16 (59 per cent) of the treated cows developed acute clinical mastitis associated with Mycobacterium smegmatis. None of the untreated cows was affected. Infected quarters were moderately hypertrophied and fine clots were present in the milk for three to four weeks. No cows showed systemic signs of illness. Studies carried out over 12 months showed that infected cows shed M smegmatis for three to four months and affected quarters remained hypertrophied in all but one cow after 12 months. The mean milk cell count of affected quarters fell slowly from 4,850,000/ml in the acute stage to 810,000/ml five months later and 620,000/ml 12 months later, suggesting that the organism persisted in the udder. The estimated mean loss in lactation yield for cows with M smegmatis mastitis was 10.8 per cent. Losses were greatest when the hind quarters were involved (mean 28 per cent for cows with both hind quarters affected). Ten of the 16 affected cows were ultimately culled owing to serious reductions in yield.
Vet Rec 1988 Mar 19
PMID:An investigation of mastitis due to S agalactiae, S uberis and M smegmatis in a dairy herd. 328 53

Mastitis in England and Wales has been controlled over the past 20 years while the average size of dairy herds has doubled to 65 cows. The incidence of clinical mastitis has been reduced from approximately 120 to 150 cases per 100 cows to less than 50 cases. The limited data on the prevalence of subclinical mastitis indicate that it has been reduced from over 50 per cent of cows infected to less than half this level. The application of the major mastitis control measures on the farm has doubled over the period 1973 to 1983 and had reached 66 to 90 per cent for individual measures by 1983. The national mean cell count in milk has been reduced from 573,000 to 352,000 cells/ml between 1971 and 1986, and the proportion of herds having annual mean cell counts below 300,000 cells/ml has increased from 15.7 per cent to 40.7 per cent in the last eight years.
Vet Rec 1988 Mar 26
PMID:Progress in controlling mastitis in England and Wales. 328 53

Sheep in a flock in which 88 per cent of the ewes had antibodies to maedi-visna virus were clinically examined for udder induration during lactation and after drying off. On both occasions about half of the ewes had indurated udders. Histological examination revealed lymphocytic mastitis associated with maedi-visna virus infection, in the udders of six of 25 hoggs (24 per cent), 21 of 39 shearlings (53.8 per cent) and 42 of 67 ewes (62.7 per cent). Distinct lung lesions were found in 8 per cent of the hoggs, 12.5 per cent of the shearlings and 10 per cent of the ewes. The results of a clinical examination of dry udders were correlated with the histological findings.
Vet Rec 1988 Apr 30
PMID:Incidence of indurative lymphocytic mastitis in a flock of sheep infected with maedi-visna virus. 339 36

Twenty-two Friesian and Friesian cross Ayrshire cows and 16 first lactation heifers were paired. Twenty were injected subcutaneously with 500 mg recombinant bovine somatotropin (sometribove) and 18 with a placebo at fortnightly intervals, starting 80 (+/- 7) days after calving, through the winter of 1986-87. The cows' weights and changes in condition, milk yields, milk solids, health and fertility were recorded regularly. Compound cake was fed at a fixed stepped rate according to the number of days since the cow calved. Silage was available on an easy-feed basis. Ten cows had their daily silage intake measured. Sometribove treated cows produced on average 27.7 kg of milk per day, 4.5 kg more than the controls. Treated heifers produced 23.5 kg per day, 2.5 kg more than the controls. Milk quality was unchanged. Treated cows gained weight during the trial, but not by as much as the controls. Control heifers also gained weight but the treated heifers lost, on average, 3 kg. Local reactions at the injection site were not felt to be of welfare concern, nor was the general effect of the extra milk production. A small number of treated animals experienced mastitis and had poorer fertility but the differences were mostly not statistically significant. If bovine somatotropin should become licensed for use in Britain it is recommended that clear guidelines should be issued on the management practices necessary for economic success and for the welfare of the treated animals.
Vet Rec 1988 May 21
PMID:Health, welfare and fertility implications of the use of bovine somatotropin in dairy cattle. 340 8

Isolates of Staphylococcus aureus (106) from bovine mastitis were tested for susceptibility to antimicrobial agents. beta-lactamase was produced by 69.8 per cent of isolates and 7.5 per cent were resistant to streptomycin (minimum inhibitory concentration more than 32 micrograms/ml). Resistance to other agents was rare. Intrinsic resistance or tolerance to beta-lactam antibiotics was not found.
Vet Rec 1986 Mar 15
PMID:Antimicrobial drug susceptibility of Staphylococcus aureus isolated from bovine mastitis. 348 21

A single dose of 250 mg cefoperazone in an oil based suspension infused into bovine quarters suffering from clinical mastitis resulted in an overall clinical cure of 82 per cent in 597 cases, as assessed by veterinarians in four countries (Sweden, Denmark, France and the United Kingdom). Of those cases for which adequate bacteriological data were available 69 per cent of 434 cases were cured. There were no reports of adverse reactions following therapy of an affected quarter. The introduction of single dose treatment represents an advance in mastitis therapy as it offers a simpler and shorter treatment than most present day mastitis therapeutics when used according to recommendations.
Vet Rec 1986 Jan 04
PMID:Field trials with cefoperazone in the treatment of bovine clinical mastitis. 351 3

Escherichia coli mastitis was first reproduced in 1903 by sticking the organism to teat orifices. E coli is very common in the environment of housed dairy cows and mastitis can easily be reproduced experimentally by the introduction of as few as 20 organisms into the teat cistern via the teat duct. It is generally accepted that this is the route of natural infection but the processes by which the organisms traverse the teat duct remain unclear. The literature is reviewed and the facts and hypotheses are considered.
Vet Rec 1986 May 03
PMID:A review of teat factors in bovine E coli mastitis. 352 Oct 57


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>